Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

Study to Evaluate D-1553 in Subjects With Lung Cancer

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
16 March 2021
Ended
17 May 2024
Enrollment
225 participants
Sites
2
Primary outcomes
Subject incidence of Dose-limiting toxicities (DLT); Number of subjects participants with adverse events; antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation
Sponsor type
Industry
Results posted
No
Last update
15 October 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation